Ventyx Biosciences: Promising Pipeline and Upcoming Data Readouts Justify Buy Rating

Canaccord Genuity analyst Edward Nash maintained a Buy rating on Ventyx Biosciences (VTYX – Research Report) yesterday and set a price target of $14.00.

Edward Nash has given his Buy rating due to a combination of factors related to Ventyx Biosciences’ promising pipeline and upcoming data readouts. The company is advancing its CNS-penetrant NLRP3 inhibitor, VTX3232, with a completed Phase II study in early Parkinson’s disease, and top-line data is expected in the second quarter of 2025. This data is anticipated to guide further development in neurodegenerative diseases, potentially expanding its therapeutic applications to conditions like Alzheimer’s and multiple sclerosis.
Additionally, Ventyx is conducting a Phase II study of VTX3232 for obesity and cardiometabolic risk factors, with results expected in the latter half of 2025. Another Phase II study for VTX2735, targeting recurrent pericarditis, is also underway, with data anticipated in the same timeframe. These trials and their potential positive outcomes underpin Nash’s confidence in the company’s future performance, justifying the Buy rating and a price target of $14.

In another report released on May 9, Piper Sandler also maintained a Buy rating on the stock with a $21.00 price target.